{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T18:08:21Z","timestamp":1786817301790,"version":"build-2736575974"},"reference-count":215,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bioorg.2025.108226","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T03:45:49Z","timestamp":1738208749000},"page":"108226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Peroxisome proliferator-activated receptors (PPARs) agonists as promising neurotherapeutics"],"prefix":"10.1016","volume":"156","author":[{"given":"Iman A.Y.","family":"Ghannam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha M.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S.","family":"Abdel-Maksoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108226_b0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","article-title":"The global prevalence of dementia: a systematic review and metaanalysis","volume":"9","author":"Prince","year":"2013","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.bioorg.2025.108226_b0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-pharmtox-010818-021807","article-title":"Nuclear receptors as therapeutic targets for neurodegenerative diseases: lost in translation","volume":"59","author":"Moutinho","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2025.108226_b0015","doi-asserted-by":"crossref","first-page":"9592","DOI":"10.1021\/acs.jmedchem.1c00186","article-title":"Targeting nuclear receptors in neurodegeneration and neuroinflammation","volume":"64","author":"Willems","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/brainsci8090177","article-title":"Neurodegenerative diseases: regenerative mechanisms and novel therapeutic approaches","volume":"8","author":"Hussain","year":"2018","journal-title":"Brain Sci."},{"key":"10.1016\/j.bioorg.2025.108226_b0025","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41593-018-0237-7","article-title":"Converging pathways in neurodegeneration, from genetics to mechanisms","volume":"21","author":"Gan","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bioorg.2025.108226_b0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tips.2023.11.004","article-title":"PPAR agonists for the treatment of neuroinflammatory diseases","volume":"45","author":"Titus","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2025.108226_b0035","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/pr.58.4.5","article-title":"International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors","volume":"58","author":"Michalik","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bioorg.2025.108226_b0040","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2337\/db12-0570","article-title":"Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator\u2013activated receptor-\u03b4 activation","volume":"62","author":"Li","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.bioorg.2025.108226_b0045","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3390\/ijms19041197","article-title":"PPAR agonists and metabolic syndrome: an established role?","volume":"19","author":"Botta","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108226_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105170","article-title":"Discovery of 4-benzyloxy and 4-(2-phenylethoxy) chalcone fibrate hybrids as novel PPAR\u03b1 agonists with anti-hyperlipidemic and antioxidant activities: design, synthesis and in vitro\/in vivo biological evaluation","volume":"115","author":"Hassan","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0055","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202100399","article-title":"Design and synthesis of novel quinazolinone-based fibrates as PPAR\u03b1 agonists with antihyperlipidemic activity","volume":"355","author":"Hassan","year":"2022","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.bioorg.2025.108226_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116279","article-title":"Novel thiazolidin-4-one benzenesulfonamide hybrids as PPAR\u03b3 agonists: design, synthesis and in vivo anti-diabetic evaluation","volume":"269","author":"Ali","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0065","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/biom14070786","article-title":"PPARs in clinical experimental medicine after 35 Years of worldwide scientific investigations and medical experiments","volume":"14","author":"Skoczy\u0144ska","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2025.108226_b0070","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.1021\/acs.jmedchem.9b02150","article-title":"l-Thyroxin and the nonclassical thyroid hormone TETRAC are potent activators of PPAR\u03b3","volume":"63","author":"Gellrich","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0075","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1021\/acs.jmedchem.6b01287","article-title":"Opportunities and challenges for fatty acid mimetics in drug discovery","volume":"60","author":"Proschak","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0080","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.tem.2012.05.001","article-title":"PPARs at the crossroads of lipid signaling and inflammation","volume":"23","author":"Wahli","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.bioorg.2025.108226_b0085","doi-asserted-by":"crossref","first-page":"27618","DOI":"10.1038\/srep27618","article-title":"Localization of PPAR isotypes in the adult mouse and human brain","volume":"6","author":"Warden","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.108226_b0090","first-page":"1031","article-title":"PPARs in the brain","volume":"1771","author":"Heneka","year":"2007","journal-title":"BBA"},{"key":"10.1016\/j.bioorg.2025.108226_b0095","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s11064-020-02993-5","article-title":"The novel role of PPAR alpha in the brain: promising target in therapy of alzheimer's disease and other neurodegenerative disorders","volume":"45","author":"W\u00f3jtowicz","year":"2020","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0100","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bioorg.2025.108226_b0105","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1111\/brv.12320","article-title":"PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation","volume":"92","author":"Zolezzi","year":"2017","journal-title":"Biol. Rev."},{"key":"10.1016\/j.bioorg.2025.108226_b0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbrc.2020.01.118","article-title":"Pemafibrate, a selective PPAR\u03b1 modulator, and fenofibrate suppress microglial activation through distinct PPAR\u03b1 and SIRT1-dependent pathways","volume":"524","author":"Ogawa","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2025.108226_b0115","first-page":"3559","article-title":"Expression of TNF\u2011\u03b1 and IL\u2011\u03b2 can be suppressed via the PPAR\u2011\u03b3\/mTOR signaling pathway in BV\u20112 microglia: a potential anti\u2011inflammation mechanism","volume":"22","author":"Zhao","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bioorg.2025.108226_b0120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12017-020-08629-9","article-title":"Recent insights on the role of PPAR-\u03b2\/\u03b4 in neuroinflammation and neurodegeneration, and its potential target for therapy","volume":"23","author":"Strosznajder","year":"2021","journal-title":"NeuroMol. Med."},{"key":"10.1016\/j.bioorg.2025.108226_b0125","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/658520","article-title":"PPAR regulation of inflammatory signaling in CNS diseases","volume":"2008","author":"Bright","year":"2008","journal-title":"PPAR Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0130","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1021\/acschemneuro.1c00085","article-title":"Glitazones activate PGC-1\u03b1 signaling via PPAR-\u03b3: a promising strategy for antiparkinsonism therapeutics","volume":"12","author":"Prabitha","year":"2021","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bioorg.2025.108226_b0135","first-page":"926","article-title":"PPARs and molecular mechanisms of transrepression","volume":"1771","author":"Ricote","year":"2007","journal-title":"BBA"},{"key":"10.1016\/j.bioorg.2025.108226_b0140","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.molcel.2006.11.024","article-title":"Initiation and beyond: multiple functions of the human mitochondrial transcription machinery","volume":"24","author":"Bonawitz","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2025.108226_b0145","doi-asserted-by":"crossref","first-page":"10411","DOI":"10.1021\/acs.jmedchem.6b00669","article-title":"Development of therapeutics that induce mitochondrial biogenesis for the treatment of acute and chronic degenerative diseases","volume":"59","author":"Cameron","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0150","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.3390\/nu13082596","article-title":"Reduced liver-specific pgc1a increases susceptibility for short-term diet-induced weight gain in male mice","volume":"13","author":"Morris","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.bioorg.2025.108226_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115717","article-title":"Peroxisom proliferator-activated receptor-\u03b3 coactivator-1\u03b1 in neurodegenerative disorders: a promising therapeutic target","volume":"215","author":"Yang","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108226_b0160","doi-asserted-by":"crossref","first-page":"39087","DOI":"10.1074\/jbc.M110.151688","article-title":"Neuronal inactivation of peroxisome proliferator-activated receptor \u03b3 coactivator 1\u03b1 (PGC-1\u03b1) protects mice from diet-induced obesity and leads to degenerative lesions","volume":"285","author":"Ma","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0165","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.3390\/ijms21093369","article-title":"Autophagy in neurodegenerative diseases: a hunter for aggregates","volume":"21","author":"Park","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108226_b0170","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/nm.3232","article-title":"The role of autophagy in neurodegenerative disease","volume":"19","author":"Nixon","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2025.108226_b0175","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.tcb.2017.01.001","article-title":"Autophagy receptors and neurodegenerative diseases","volume":"27","author":"Deng","year":"2017","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bioorg.2025.108226_b0180","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.neuron.2017.01.022","article-title":"Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities","volume":"93","author":"Menzies","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.bioorg.2025.108226_b0185","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1172\/JCI73944","article-title":"Autophagy and neurodegeneration","volume":"125","author":"Frake","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2025.108226_b0190","series-title":"Synthesis of Best-Seller Drugs","first-page":"285","article-title":"Chapter 20 - Hypolipidemic and Antihyperlipidemic Drugs","author":"Vardanyan","year":"2016"},{"key":"10.1016\/j.bioorg.2025.108226_b0195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a new selective PPAR\u03b1 Modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases","volume":"22","author":"Yamashita","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.bioorg.2025.108226_b0200","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0205","series-title":"Synthesis of Best-Seller Drugs","first-page":"419","article-title":"Chapter 26 - Hyperglycemic and Hypoglycemic Drugs","author":"Vardanyan","year":"2016"},{"key":"10.1016\/j.bioorg.2025.108226_b0210","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/01.jnen.0000178852.83680.3c","article-title":"The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke","volume":"64","author":"Pereira","year":"2005","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.bioorg.2025.108226_b0215","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1016\/j.bmcl.2011.06.088","article-title":"Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPAR\u03b3 partial agonist","volume":"21","author":"Sime","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108226_b0220","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.3390\/ijms19082189","article-title":"The opportunities and challenges of peroxisome proliferator-activated receptors ligands in clinical drug discovery and development","volume":"19","author":"Hong","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108226_b0225","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/13543776.2012.699042","article-title":"Therapeutic modulators of peroxisome proliferator-activated receptors PPAR): a patent review (2008-present","volume":"22","author":"Lamers","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2025.108226_b0230","doi-asserted-by":"crossref","first-page":"10109","DOI":"10.1021\/acs.jmedchem.9b01882","article-title":"Targeting peroxisome proliferator-activated receptor delta (PPAR\u03b4): a medicinal chemistry perspective","volume":"63","author":"Kadayat","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0235","first-page":"716","article-title":"Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study, Lancet","volume":"2","author":"Jones","year":"2017","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2025.108226_b0240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.4003","article-title":"PPAR-\u03b4 is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically","volume":"22","author":"Dickey","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2025.108226_b0245","doi-asserted-by":"crossref","first-page":"21117","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.108226_b0250","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/JAD-151013","article-title":"T3D-959: a multi-faceted disease remedial drug candidate for the treatment of alzheimer's disease","volume":"51","author":"Tong","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bioorg.2025.108226_b0255","doi-asserted-by":"crossref","first-page":"17321","DOI":"10.1523\/JNEUROSCI.1569-12.2012","article-title":"PPAR\u03b3\/RXR\u03b1-induced and CD36-mediated microglial amyloid-\u03b2 phagocytosis results in cognitive improvement in amyloid precursor protein\/presenilin 1 mice","volume":"32","author":"Yamanaka","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bioorg.2025.108226_b0260","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1517\/13543784.2012.703178","article-title":"Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis","volume":"21","author":"Dunkel","year":"2012","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.bioorg.2025.108226_b0265","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1016\/j.bmcl.2007.05.066","article-title":"Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists","volume":"17","author":"Yamazaki","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108226_b0270","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.bjp.0705232","article-title":"PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect","volume":"139","author":"Trifilieff","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108226_b0275","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4093\/dmj.2020.0272","article-title":"Lobeglitazone: a novel thiazolidinedione for the management of type 2 diabetes mellitus","volume":"45","author":"Bae","year":"2021","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.bioorg.2025.108226_b0280","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0960-894X(03)00207-5","article-title":"Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)\u2013synthesis and biological activity","volume":"13","author":"Sznaidman","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108226_b0285","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1021\/bi400321p","article-title":"Peroxisome proliferation-activated receptor \u03b4 agonist GW0742 interacts weakly with multiple nuclear receptors, including the vitamin D receptor","volume":"52","author":"Nandhikonda","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2025.108226_b0290","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1055\/s-0035-1549965","article-title":"Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a\/\u03b3 modulator, on adipogenesis and glucose metabolism in diabetic obese mice","volume":"123","author":"Goto","year":"2015","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.bioorg.2025.108226_b0295","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2025.108226_b0300","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.brainres.2006.12.011","article-title":"Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not","volume":"1135","author":"Kreisler","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0305","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.nbd.2014.08.011","article-title":"Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-\u03b3 agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease","volume":"71","author":"Pisanu","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bioorg.2025.108226_b0310","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.1471-4159.2002.00990.x","article-title":"Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease","volume":"82","author":"Breidert","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bioorg.2025.108226_b0315","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/bjp.2008.78","article-title":"The PPAR\u03b3 agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B","volume":"154","author":"Quinn","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108226_b0320","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13024-016-0090-7","article-title":"Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation","volume":"11","author":"Pinto","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bioorg.2025.108226_b0325","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s00125-017-4499-5","article-title":"Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study","volume":"61","author":"Lu","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.bioorg.2025.108226_b0330","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1742-2094-8-91","article-title":"The PPAR-\u03b3 agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys","volume":"8","author":"Swanson","year":"2011","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bioorg.2025.108226_b0335","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4089214","article-title":"Neuroprotective effect and mechanism of thiazolidinedione on dopaminergic neurons in vivo and in vitro in parkinson's disease","volume":"2017","author":"Wang","year":"2017","journal-title":"PPAR Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0340","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.expneurol.2017.11.009","article-title":"Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats","volume":"300","author":"Bonato","year":"2018","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bioorg.2025.108226_b0345","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.pharep.2018.11.005","article-title":"PPAR-\u03b3 agonist pioglitazone reduces microglial proliferation and NF-\u03baB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson's disease","volume":"71","author":"Machado","year":"2019","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bioorg.2025.108226_b0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001854","article-title":"Glitazone treatment and incidence of Parkinson's disease among people with diabetes: a retrospective cohort study","volume":"12","author":"Brauer","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.bioorg.2025.108226_b0355","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.brainresbull.2021.05.011","article-title":"Effect of lobeglitazone on motor function in rat model of Parkinson's disease with diabetes co-morbidity","volume":"173","author":"Hassanzadeh","year":"2021","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bioorg.2025.108226_b0360","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuroscience.2015.04.026","article-title":"Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPAR\u03b3 agonist in vitro and in MPTP-treated mice","volume":"302","author":"Lecca","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.bioorg.2025.108226_b0365","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1111\/bph.14214","article-title":"Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPAR\u03b3 agonist MDG548 in Parkinson's disease models","volume":"175","author":"Lecca","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108226_b0370","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/582809","article-title":"Neuroprotective properties of a novel non-thiazoledinedione partial PPAR- gamma agonist against MPTP","volume":"2013","author":"Swanson","year":"2013","journal-title":"PPAR Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0375","first-page":"042","article-title":"Novel glitazone attenuates rotenone-induced toxicity in mouse model of Parkinson\u2019s disease","volume":"11","author":"Shetty","year":"2021","journal-title":"J Appl. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2025.108226_b0380","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1021\/acschemneuro.3c00084","article-title":"Uncovering novel therapeutic targets for Parkinson\u2019s disease","volume":"14","author":"Soni","year":"2023","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bioorg.2025.108226_b0385","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1021\/acsomega.2c07521","article-title":"Design and development of novel glitazones for activation of PGC-1\u03b1 signaling via PPAR-\u03b3 agonism: a promising therapeutic approach against Parkinson's disease","volume":"8","author":"Prabhakaran","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2025.108226_b0390","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1471-4159.2008.05388.x","article-title":"PPAR: a therapeutic target in Parkinson's disease","volume":"106","author":"Chaturvedi","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bioorg.2025.108226_b0395","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1124\/jpet.106.115758","article-title":"Neuroprotective efficacy of the peroxisome proliferator-activated receptor \u03b4-selective agonists in vitro and in vivo","volume":"320","author":"Iwashita","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2025.108226_b0400","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2174\/1567202611666140318114037","article-title":"A PPAR-\u03b2\/\u03b4 agonist is neuroprotective and decreases cognitive impairment in a rodent model of Parkinson's disease","volume":"11","author":"Das","year":"2014","journal-title":"Curr. Neurovasc. Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0405","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/373560","article-title":"Neuroprotective mechanisms of PPAR\u03b4: modulation of oxidative stress and inflammatory processes","volume":"2011","author":"Schnegg","year":"2011","journal-title":"PPAR Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0410","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bbr.2018.06.005","article-title":"PPAR\u00df\/\u03b4 agonist alleviates NLRP3 inflammasome-mediated neuroinflammation in the MPTP mouse model of Parkinson\u2019s disease","volume":"356","author":"Chen","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2020.100871","article-title":"PPAR\u03b4 and its ligand erucic acid may act anti-tumoral, neuroprotective, and myelin protective in neuroblastoma, glioblastoma, and Parkinson's disease","volume":"78","author":"Altinoz","year":"2021","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.bioorg.2025.108226_b0420","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuroscience.2013.02.058","article-title":"A peroxisome proliferator-activated receptor-\u03b4 agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease","volume":"240","author":"Martin","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.bioorg.2025.108226_b0425","article-title":"Neuroprotective potential of peroxisome proliferator activated receptor- \u03b1 agonist in cognitive impairment in Parkinson's disease: behavioral","volume":"2014","author":"Uppalapati","year":"2014","journal-title":"Biochem. PBPK Profile PPAR Res"},{"key":"10.1016\/j.bioorg.2025.108226_b0430","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pnpbp.2014.02.009","article-title":"PPAR-\u03b1 agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease","volume":"53","author":"Barbiero","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bioorg.2025.108226_b0435","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainres.2018.09.036","article-title":"Neuroprotective effects of MHY908, a PPAR \u03b1\/\u03b3 dual agonist, in a MPTP-induced Parkinson's disease model","volume":"1704","author":"Lee","year":"2019","journal-title":"Brain Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0440","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/nn.4018","article-title":"Three dimensions of the amyloid hypothesis: time, space and 'wingmen'","volume":"18","author":"Musiek","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bioorg.2025.108226_b0445","series-title":"Nuclear Receptors: the Art and Science of Modulator Design and Discovery","first-page":"249","article-title":"Chapter 10 Design of Novel PPAR Agonist for Neurodegenerative Disease","author":"Steinke","year":"2021"},{"key":"10.1016\/j.bioorg.2025.108226_b0450","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2174\/157015911798376325","article-title":"Impact and therapeutic potential of PPARs in Alzheimer's disease","volume":"9","author":"Heneka","year":"2011","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bioorg.2025.108226_b0455","doi-asserted-by":"crossref","first-page":"41057","DOI":"10.1074\/jbc.M505160200","article-title":"Peroxisomal proliferation protects from beta-amyloid neurodegeneration","volume":"280","author":"Santos","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0460","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3233\/JAD-2012-120397","article-title":"Peroxisome proliferators reduce spatial memory impairment, synaptic failure, and neurodegeneration in brains of a double transgenic mice model of Alzheimer's disease","volume":"33","author":"Inestrosa","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bioorg.2025.108226_b0465","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3390\/molecules25051062","article-title":"Is there a future for PPARs in the treatment of neuropsychiatric disorders?","volume":"25","author":"Tufano","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.108226_b0470","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1021\/acschemneuro.1c00516","article-title":"PPAR-\u03b1 agonist GW7647 protects against oxidative stress and iron deposit via GPx4 in a transgenic mouse model of Alzheimer's diseases","volume":"13","author":"Qu","year":"2022","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bioorg.2025.108226_b0475","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/156720511796391935","article-title":"Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies","volume":"8","author":"Harrington","year":"2011","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0480","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000318845","article-title":"Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study","volume":"30","author":"Gold","year":"2010","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.bioorg.2025.108226_b0485","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1021\/acschemneuro.1c00022","article-title":"Neuroprotective efficacy of co-encapsulated rosiglitazone and vorinostat nanoparticle on streptozotocin induced mice model of Alzheimer disease","volume":"12","author":"Sarathlal","year":"2021","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bioorg.2025.108226_b0490","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/ana.24439","article-title":"Effect of pioglitazone medication on the incidence of dementia","volume":"78","author":"Heneka","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bioorg.2025.108226_b0495","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jdiacomp.2017.01.006","article-title":"Effects of pioglitazone on the incidence of dementia in patients with diabetes","volume":"31","author":"Chou","year":"2017","journal-title":"J. Diabetes Complications"},{"key":"10.1016\/j.bioorg.2025.108226_b0500","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/403896","article-title":"PPARs in Alzheimer's disease","volume":"2008","author":"Kummer","year":"2008","journal-title":"PPAR Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0505","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.bbrc.2009.04.047","article-title":"PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons","volume":"383","author":"Du","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2025.108226_b0510","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fnagi.2019.00178","article-title":"Pioglitazone reduces \u03b2 amyloid levels via inhibition of PPAR\u03b3 phosphorylation in a neuronal model of Alzheimer's disease","volume":"11","author":"Quan","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bioorg.2025.108226_b0515","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1073\/pnas.0503839103","article-title":"Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma","volume":"103","author":"Sastre","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.bioorg.2025.108226_b0520","doi-asserted-by":"crossref","first-page":"9796","DOI":"10.1523\/JNEUROSCI.23-30-09796.2003","article-title":"Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase","volume":"23","author":"Sastre","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bioorg.2025.108226_b0525","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.3892\/mmr.2017.6342","article-title":"Pioglitazone ameliorates A\u03b242 deposition in rats with diet-induced insulin resistance associated with AKT\/GSK3\u03b2 activation","volume":"15","author":"Yang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bioorg.2025.108226_b0530","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1007\/s12035-019-1586-2","article-title":"Reverting metabolic dysfunction in cortex and cerebellum of APP\/PS1 mice, a model for Alzheimer's disease by pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR\u03b3) agonist","volume":"56","author":"Chang","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bioorg.2025.108226_b0535","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00702-014-1294-z","article-title":"Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice","volume":"122","author":"Yu","year":"2015","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.bioorg.2025.108226_b0540","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trci.2016.11.002","article-title":"Combination treatment with leptin and pioglitazone in a mouse model ofAlzheimer's disease","volume":"3","author":"Fernandez-Martos","year":"2017","journal-title":"Alzheimers Dement (n y)"},{"key":"10.1016\/j.bioorg.2025.108226_b0545","article-title":"Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2025.108226_b0550","doi-asserted-by":"crossref","first-page":"10117","DOI":"10.1523\/JNEUROSCI.5268-11.2012","article-title":"Mechanisms underlying the rapid peroxisome proliferator-activated receptor-\u03b3-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease","volume":"32","author":"Mandrekar-Colucci","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bioorg.2025.108226_b0555","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.bbrc.2016.08.016","article-title":"Pioglitazone prevents tau oligomerization","volume":"478","author":"Hamano","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2025.108226_b0560","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/j.1471-4159.2006.03931.x","article-title":"Troglitazone, a peroxisome proliferator-activated receptor-gamma agonist, decreases tau phosphorylation in CHOtau4R cells","volume":"98","author":"d'Abramo","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bioorg.2025.108226_b0565","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40266-014-0228-7","article-title":"Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis","volume":"32","author":"Liu","year":"2015","journal-title":"Drugs Aging"},{"key":"10.1016\/j.bioorg.2025.108226_b0570","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/00207454.2015.1015722","article-title":"The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis","volume":"126","author":"Cheng","year":"2016","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.bioorg.2025.108226_b0575","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.bbrc.2017.06.146","article-title":"INT131 increases dendritic arborization and protects against A\u03b2 toxicity by inducing mitochondrial changes in hippocampal neurons","volume":"490","author":"Godoy","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2025.108226_b0580","doi-asserted-by":"crossref","first-page":"33247","DOI":"10.1039\/D4RA06330A","article-title":"Novel PPAR-\u03b3 agonists as potential neuroprotective agents against Alzheimer's disease: rational design, synthesis, in silico evaluation, PPAR-\u03b3 binding assay and transactivation and expression studies","volume":"14","author":"Priya","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.108226_b0585","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2174\/1567205014666170203141717","article-title":"Neuroinflammation and Alzheimer's disease: implications for microglial activation","volume":"14","author":"Regen","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0590","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","article-title":"Neuroinflammation in Alzheimer's disease: current evidence and future directions","volume":"12","author":"Calsolaro","year":"2016","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.bioorg.2025.108226_b0595","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.902047","article-title":"Peroxisomal proliferator-activated receptor \u03b2\/\u03b4 deficiency induces cognitive alterations","volume":"13","author":"Espinosa-Jim\u00e9nez","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108226_b0600","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2174\/156720509789207949","article-title":"A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimers disease","volume":"6","author":"Kalinin","year":"2009","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0605","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1021\/acschemneuro.3c00320","article-title":"Neuroprotective effect of saroglitazar on scopolamine-induced Alzheimer\u2019s in rats: insights into the underlying mechanisms","volume":"14","author":"Sandeep Ganesh","year":"2023","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bioorg.2025.108226_b0610","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3390\/cells12081116","article-title":"Selective PPAR-Delta\/PPAR-gamma activation improves cognition in a model of Alzheimer's disease","volume":"12","author":"Steinke","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.108226_b0615","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.4103\/1673-5374.386410","article-title":"Dual PPAR delta\/gamma agonists offer therapeutic potential for Alzheimer's disease","volume":"19","author":"Steinke","year":"2024","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0620","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s13311-022-01275-y","article-title":"Synthetic PPAR Agonist DTMB Alleviates Alzheimer\u2019s disease pathology by inhibition of chronic microglial inflammation in 5xFAD mice","volume":"19","author":"Oh","year":"2022","journal-title":"Neurother"},{"key":"10.1016\/j.bioorg.2025.108226_b0625","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/jnnp.57.9.1064","article-title":"Multiple sclerosis in black South Africans and Zimbabweans","volume":"57","author":"Dean","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bioorg.2025.108226_b0630","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa1100648","article-title":"Inflammatory cortical demyelination in early multiple sclerosis","volume":"365","author":"Lucchinetti","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108226_b0635","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1742-2094-8-127","article-title":"Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis","volume":"8","author":"Weinstock-Guttman","year":"2011","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.bioorg.2025.108226_b0640","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","article-title":"Experimental autoimmune encephalomyelitis EAE) as a model for multiple sclerosis (MS)","volume":"164","author":"Constantinescu","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108226_b0645","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neulet.2013.08.069","article-title":"Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis","volume":"554","author":"Szalardy","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bioorg.2025.108226_b0650","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.10206","article-title":"Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis","volume":"51","author":"Feinstein","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bioorg.2025.108226_b0655","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1084\/jem.20082771","article-title":"The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity","volume":"206","author":"Klotz","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bioorg.2025.108226_b0660","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jneuroim.2018.06.001","article-title":"Pioglitazone is superior to quetiapine, clozapine and tamoxifen at alleviating experimental autoimmune encephalomyelitis in mice","volume":"321","author":"Chedrawe","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bioorg.2025.108226_b0665","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jneuroim.2003.11.010","article-title":"Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis","volume":"148","author":"Diab","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bioorg.2025.108226_b0670","first-page":"1013","article-title":"Docosahexaenoic acid promotes oligodendrocyte differentiation via PPAR-\u03b3 signalling and prevents tumor necrosis factor-\u03b1-dependent maturational arrest","volume":"2017","author":"Bernardo","year":"1862","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.bioorg.2025.108226_b0675","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.expneurol.2015.07.014","article-title":"Peroxisome proliferator activated receptor-\u03b3 agonists protect oligodendrocyte progenitors against tumor necrosis factor-alpha-induced damage: effects on mitochondrial functions and differentiation","volume":"271","author":"De Nuccio","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bioorg.2025.108226_b0680","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jneuroim.2004.12.015","article-title":"Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis","volume":"161","author":"Storer","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bioorg.2025.108226_b0685","doi-asserted-by":"crossref","first-page":"9329","DOI":"10.3390\/ijms21239329","article-title":"Altered PPAR\u03b3 expression promotes myelin-induced foam cell formation in macrophages in multiple sclerosis","volume":"21","author":"Wouters","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108226_b0690","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1189\/jlb.0803402","article-title":"Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients","volume":"75","author":"Schmidt","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bioorg.2025.108226_b0695","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0165-5728(01)00285-5","article-title":"Amelioration of experimental autoimmune encephalomyelitis in C57BL\/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma","volume":"116","author":"Niino","year":"2001","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bioorg.2025.108226_b0700","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jneuroim.2005.07.006","article-title":"Protective effects of a peroxisome proliferator-activated receptor-beta\/delta agonist in experimental autoimmune encephalomyelitis","volume":"168","author":"Polak","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bioorg.2025.108226_b0705","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.4049\/jimmunol.1801200","article-title":"Peroxisome proliferator\u2013activated receptor-\u03b4 acts within peripheral myeloid cells to limit Th cell priming during experimental autoimmune encephalomyelitis","volume":"203","author":"Drohomyrecky","year":"2019","journal-title":"J Immun"},{"key":"10.1016\/j.bioorg.2025.108226_b0710","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12974-020-01899-x","article-title":"CD36-mediated uptake of myelin debris by macrophages and microglia reduces neuroinflammation","volume":"17","author":"Grajchen","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.bioorg.2025.108226_b0715","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.brainres.2010.12.059","article-title":"PPAR\u03b4 deficient mice develop elevated Th1\/Th17 responses and prolonged experimental autoimmune encephalomyelitis","volume":"1376","author":"Kanakasabai","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0720","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.bioorg.2025.108226_b0725","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/sj.embor.7400250","article-title":"Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in Molecular Medicine Review Series","volume":"5","author":"Landles","year":"2004","journal-title":"EMBO Rep"},{"key":"10.1016\/j.bioorg.2025.108226_b0730","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/hmg\/ddr541","article-title":"Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease","volume":"21","author":"Johri","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bioorg.2025.108226_b0735","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/hmg\/ddq322","article-title":"Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma","volume":"19","author":"Chiang","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bioorg.2025.108226_b0740","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/jnc.12190","article-title":"Neuroprotective effects of PPAR-\u03b3 agonist rosiglitazone in N171-82Q mouse model of Huntington's disease","volume":"125","author":"Jin","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bioorg.2025.108226_b0745","first-page":"679","article-title":"Sporadic and hereditary amyotrophic lateral sclerosis (ALS)","volume":"2015","author":"Ajroud-Driss","year":"1852","journal-title":"BBA"},{"key":"10.1016\/j.bioorg.2025.108226_b0750","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Kiernan","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2025.108226_b0755","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/hmg\/ddv477","article-title":"Preferential PPAR-\u03b1 activation reduces neuroinflammation, and blocks neurodegeneration in vivo","volume":"25","author":"Esmaeili","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bioorg.2025.108226_b0760","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/582075","article-title":"A pilot trial of pioglitazone HCl and tretinoin in ALS: cerebrospinal fluid biomarkers to monitor drug efficacy and predict rate of disease progression","volume":"2012","author":"Levine","year":"2012","journal-title":"Neurol. Res. Int."},{"key":"10.1016\/j.bioorg.2025.108226_b0765","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.expneurol.2004.10.007","article-title":"Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis","volume":"191","author":"Kiaei","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bioorg.2025.108226_b0770","doi-asserted-by":"crossref","first-page":"7805","DOI":"10.1523\/JNEUROSCI.2038-05.2005","article-title":"The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice","volume":"25","author":"Sch\u00fctz","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bioorg.2025.108226_b0775","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","article-title":"Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications","volume":"166","author":"Mirza","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0780","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.3390\/biomedicines9121914","article-title":"Role of phytoconstituents as PPAR agonists: implications for neurodegenerative disorders","volume":"9","author":"Sanjay","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2025.108226_b0785","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/hmg\/ddu587","article-title":"PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43","volume":"24","author":"Joardar","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bioorg.2025.108226_b0790","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/418765","article-title":"Peroxisome proliferator-activated receptor-\u03b3 in amyotrophic lateral sclerosis and Huntington\u2032s disease","volume":"2008","author":"Kiaei","year":"2008","journal-title":"PPAR Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0795","doi-asserted-by":"crossref","first-page":"35899","DOI":"10.1074\/jbc.M112.366419","article-title":"The peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) controls natural protective mechanisms against lipid peroxidation in amyotrophic lateral sclerosis","volume":"287","author":"Benedusi","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0800","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1523\/JNEUROSCI.3018-19.2021","article-title":"Gemfibrozil protects dopaminergic neurons in a mouse model of parkinson's disease via ppar\u03b1-dependent astrocytic GDNF pathway","volume":"41","author":"Gottschalk","year":"2021","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bioorg.2025.108226_b0805","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.toxlet.2012.07.016","article-title":"Rosiglitazone, a PPAR-\u03b3 agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats","volume":"213","author":"Lee","year":"2012","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.bioorg.2025.108226_b0810","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.neuroscience.2011.07.046","article-title":"Rosiglitazone decreases peroxisome proliferator receptor-\u03b3 levels in microglia and inhibits TNF-\u03b1 production: new evidences on neuroprotection in a progressive Parkinson's disease model","volume":"194","author":"Carta","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.bioorg.2025.108226_b0815","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1460-9568.2009.06657.x","article-title":"PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease","volume":"29","author":"Schintu","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bioorg.2025.108226_b0820","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jneuroim.2012.03.010","article-title":"Full and partial peroxisome proliferation-activated receptor-\u03b3 agonists, but not \u03b4 agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression","volume":"246","author":"Sadeghian","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bioorg.2025.108226_b0825","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jneuroim.2007.09.029","article-title":"Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-kappaB and JNK activation and suppression of COX-2 activity","volume":"192","author":"Xing","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bioorg.2025.108226_b0830","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1471-4159.2006.04327.x","article-title":"Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system","volume":"100","author":"Hunter","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bioorg.2025.108226_b0835","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neulet.2007.12.019","article-title":"Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague\u2013Dawley rats","volume":"432","author":"Hunter","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bioorg.2025.108226_b0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176117","article-title":"Repurposing and clinical attributes of antidiabetic drugs for the treatment of neurodegenerative disorders","volume":"961","author":"Birajdar","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108226_b0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107705","article-title":"PPAR\u03b3\/PGC1\u03b1 signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders","volume":"219","author":"Jamwal","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.108226_b0850","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1093\/hmg\/dds355","article-title":"Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice","volume":"21","author":"Dumont","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bioorg.2025.108226_b0855","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/15548627.2019.1596488","article-title":"Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model","volume":"16","author":"Luo","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.bioorg.2025.108226_b0860","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1194\/jlr.R075556","article-title":"Therapeutic potential of nuclear receptor agonists in Alzheimer's disease","volume":"58","author":"Moutinho","year":"2017","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0865","first-page":"1042","article-title":"Exploring rosiglitazone's potential to treat alzheimer's disease through the modulation of brain-derived neurotrophic factor","volume":"12","author":"Nelson","year":"2023","journal-title":"Biology (basel)"},{"key":"10.1016\/j.bioorg.2025.108226_b0870","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00044-020-02687-1","article-title":"Sulfur-containing therapeutics in the treatment of Alzheimer's disease","volume":"30","author":"Zhu","year":"2021","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0875","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3233\/JAD-2010-100939","article-title":"A multi-center randomized proof-of-concept clinical trial applying [18F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease","volume":"22","author":"Tzimopoulou","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bioorg.2025.108226_b0880","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JAD-201610","article-title":"A precision medicine approach to treating Alzheimer's disease using rosiglitazone therapy: a biomarker analysis of the REFLECT trials","volume":"81","author":"O'Bryant","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bioorg.2025.108226_b0885","first-page":"950","article-title":"Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study","volume":"13","author":"Watson","year":"2005","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.bioorg.2025.108226_b0890","doi-asserted-by":"crossref","first-page":"S427","DOI":"10.3233\/JAD-179923","article-title":"Targeting insulin for alzheimer's disease: mechanisms, status and potential directions","volume":"64","author":"Lee","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bioorg.2025.108226_b0895","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068612","article-title":"Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-\u03b2 and cerebrovascular pathology","volume":"8","author":"Papadopoulos","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2025.108226_b0900","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/brain\/awh452","article-title":"Acute treatment with the PPAR\u03b3 agonist pioglitazone and ibuprofen reduces glial inflammation and A\u03b21\u201342 levels in APPV717I transgenic mice","volume":"128","author":"Heneka","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.bioorg.2025.108226_b0905","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1474-4422(21)00043-0","article-title":"Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Burns","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bioorg.2025.108226_b0910","doi-asserted-by":"crossref","first-page":"886","DOI":"10.14283\/jpad.2023.115","article-title":"Genotypic effects of the TOMM40'523 variant and APOE on longitudinal cognitive change over 4 years: the TOMMORROW study","volume":"10","author":"Zou","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.bioorg.2025.108226_b0915","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.trci.2019.09.010","article-title":"The TOMMORROW study: design of an Alzheimer's disease delay-of-onset clinical trial","volume":"5","author":"Burns","year":"2019","journal-title":"Alzheimers Dement (n y)"},{"key":"10.1016\/j.bioorg.2025.108226_b0920","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12974-014-0229-9","article-title":"Activation of the nuclear receptor PPAR\u03b4 is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammation","volume":"12","author":"Malm","year":"2015","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bioorg.2025.108226_b0925","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2174\/156720509789207949","article-title":"A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease","volume":"6","author":"Kalinin","year":"2009","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0930","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40120-022-00363-7","article-title":"A narrative review on axonal neuroprotection in multiple sclerosis","volume":"11","author":"Collongues","year":"2022","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.bioorg.2025.108226_b0935","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037885","article-title":"A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis","volume":"7","author":"Dupuis","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2025.108226_b0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117170","article-title":"Impact of natural compounds on peroxisome proliferator-activated receptor: Molecular effects and its importance as a novel therapeutic target for neurological disorders","volume":"283","author":"Zhu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108149","article-title":"New triterpenoid saponins isolated from the leaves of Astragalus membranaceus (Fisch.) Bge. and their neuroprotective effects","volume":"156","author":"Xu","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0950","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s11064-018-02705-0","article-title":"Cinnamic acid protects the nigrostriatum in a mouse model of parkinson's disease via peroxisome proliferator-activated receptor\u03b1","volume":"44","author":"Prorok","year":"2019","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0955","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.nbd.2018.12.007","article-title":"Cinnamic acid activates PPAR\u03b1 to stimulate Lysosomal biogenesis and lower Amyloid plaque pathology in an Alzheimer's disease mouse model","volume":"124","author":"Chandra","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bioorg.2025.108226_b0960","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1021\/acs.jafc.9b07467","article-title":"Alternative pathway to the formation of trans-cinnamic acid derived from l-phenylalanine in tea (Camellia sinensis) plants and other plants","volume":"68","author":"Zeng","year":"2020","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0965","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.fitote.2015.02.012","article-title":"A comprehensive scientific overview of Garcinia cambogia","volume":"102","author":"Semwal","year":"2015","journal-title":"Fitoterapia"},{"key":"10.1016\/j.bioorg.2025.108226_b0970","doi-asserted-by":"crossref","first-page":"11866","DOI":"10.1074\/jbc.RA120.013303","article-title":"Garcinoic acid prevents \u03b2-amyloid (A\u03b2) deposition in the mouse brain","volume":"295","author":"Marinelli","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108226_b0975","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2990.2011.01248.x","article-title":"\u03949-tetrahydrocannabinol (\u03949-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease","volume":"38","author":"Carroll","year":"2012","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.bioorg.2025.108226_b0980","doi-asserted-by":"crossref","first-page":"46603","DOI":"10.18632\/oncotarget.10314","article-title":"Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis","volume":"7","author":"Zeissler","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.108226_b0985","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nbd.2016.06.013","article-title":"Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action","volume":"94","author":"Dos-Santos-Pereira","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bioorg.2025.108226_b0990","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ptr.5095","article-title":"Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPAR\u03b3 involvement","volume":"28","author":"Scuderi","year":"2014","journal-title":"Phytother. Res."},{"key":"10.1016\/j.bioorg.2025.108226_b0995","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.fitote.2016.11.010","article-title":"Target regulation of PI3K\/Akt\/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis","volume":"116","author":"Giacoppo","year":"2017","journal-title":"Fitoterapia"},{"key":"10.1016\/j.bioorg.2025.108226_b1000","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s13311-014-0304-z","article-title":"Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6\/2 mice and 3-nitropropionate-lesioned mice","volume":"12","author":"Valdeolivas","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bioorg.2025.108226_b1005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3389\/fnins.2019.00291","article-title":"Icariin attenuates M1 activation of microglia and A\u03b2 plaque accumulation in the hippocampus and prefrontal cortex by up-regulating PPAR\u03b3 in restraint\/isolation-stressed APP\/PS1 mice","volume":"13","author":"Wang","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bioorg.2025.108226_b1010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41401-019-0300-2","article-title":"Icariside II inhibits lipopolysaccharide-induced inflammation and amyloid production in rat astrocytes by regulating IKK\/I\u03baB\/NF-\u03baB\/BACE1 signaling pathway","volume":"41","author":"Zheng","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bioorg.2025.108226_b1015","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3389\/fphar.2018.01211","article-title":"Icariside II ameliorates cognitive impairments induced by chronic cerebral hypoperfusion by inhibiting the amyloidogenic pathway: involvement of BDNF\/TrkB\/CREB signaling and up-regulation of PPAR\u03b1 and PPAR\u03b3 in rats","volume":"9","author":"Yin","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108226_b1020","first-page":"1786","article-title":"Cyanidin 3-O-\u03b2-glucopyranoside activates peroxisome proliferator-activated receptor-\u03b3 and alleviates cognitive impairment in the APPswe\/PS1\u0394E9 mouse model","volume":"2016","author":"Song","year":"1862","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.bioorg.2025.108226_b1025","first-page":"1264","article-title":"Cyanidin-3-O-glucoside: physical-chemistry","volume":"21","author":"Olivas-Aguirre","year":"2016","journal-title":"Foodomics Health Effects Molecules"},{"key":"10.1016\/j.bioorg.2025.108226_b1030","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3389\/fonc.2019.00942","article-title":"The natural flavonoid galangin elicits apoptosis, pyroptosis, and autophagy in glioblastoma","volume":"9","author":"Kong","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.108226_b1035","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.biopha.2018.09.154","article-title":"Chemopreventive mechanisms of galangin against hepatocellular carcinoma: a review","volume":"109","author":"Fang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.108226_b1040","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bcp.2017.07.021","article-title":"Anti-inflammatory mechanism of galangin in lipopolysaccharide-stimulated microglia: critical role of PPAR-\u03b3 signaling pathway","volume":"144","author":"Choi","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108226_b1045","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10072-013-1594-3","article-title":"Effect of naringenin on brain insulin signaling and cognitive functions in ICV-STZ induced dementia model of rats","volume":"35","author":"Yang","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.bioorg.2025.108226_b1050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.fct.2018.08.028","article-title":"Neuroprotective effect of naringin, a flavone glycoside in quinolinic acid-induced neurotoxicity: possible role of PPAR-\u03b3, Bax\/Bcl-2, and caspase-3","volume":"121","author":"Cui","year":"2018","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.bioorg.2025.108226_b1055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/ph12010011","article-title":"The therapeutic potential of naringenin: a review of clinical trials","volume":"12","author":"Salehi","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bioorg.2025.108226_b1060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejphar.2015.07.001","article-title":"Naringenin improves learning and memory in an Alzheimer's disease rat model: Insights into the underlying mechanisms","volume":"764","author":"Ghofrani","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108226_b1065","doi-asserted-by":"crossref","first-page":"12621","DOI":"10.1039\/D1FO02407H","article-title":"Baicalin inhibits APEC-induced lung injury by regulating gut microbiota and SCFA production","volume":"12","author":"Peng","year":"2021","journal-title":"Food Funct."},{"key":"10.1016\/j.bioorg.2025.108226_b1070","doi-asserted-by":"crossref","first-page":"e1142","DOI":"10.1212\/NXI.0000000000001142","article-title":"Baicalin promotes CNS remyelination via PPAR\u03b3 Signal Pathway","volume":"9","author":"Ai","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.bioorg.2025.108226_b1075","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201700633","article-title":"Glycyrrhiza uralensis and semilicoisoflavone B reduce A\u03b2 secretion by increasing PPAR\u03b3 expression and inhibiting STAT3 phosphorylation to inhibit BACE1 expression","volume":"62","author":"Gu","year":"2018","journal-title":"Mol. Nutr. Food Res."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825001063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825001063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T02:09:46Z","timestamp":1758852586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825001063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":215,"alternative-id":["S0045206825001063"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108226","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peroxisome proliferator-activated receptors (PPARs) agonists as promising neurotherapeutics","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108226","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108226"}}